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Abstract
Background: This article sets up the initial discussion of the evolution of biopharmaceutical innovation in China 
through the perspective of sectoral innovation system (SIS). 
Methods: Two data sources including archival documentary data and field interviews were used in this study. 
Archival documentary data was collected from China Food and Drug Administration (CFDA) and Chinese 
National Knowledge Infrastructure (CNKI). In addition, industrial practitioners and leading researchers in 
academia were interviewed.
Results: Biopharmaceutical in China was established through international knowledge transfer. The firms played 
more active role in commercializing biopharmaceutical in China though universities and research institutes were 
starting to interact with local firms and make contribution to biopharmaceutical industrialization. The transition 
of the Chinese government’s policies continuously shapes the evolution of biopharmaceutical sector. Policies 
have been dramatic changes before and after 1980s to encourage developing biopharmaceutical as a competitive 
industry for China. 
Conclusion: A SIS for biopharmaceutical has been shaped in China. However, currently biopharmaceutical is still 
a small sector in China, and for the further growth of the industry more synthetic policies should be implemented. 
Not only the policy supports towards the research and innovation of biopharmaceuticals in the early stage of 
development should be attended, but also commercialization of biopharmaceutical products in the later stage of 
sales.
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Implications for policy makers
• Biopharmaceutical innovation demands the establishment of a sustainable innovation system that needs many efforts across decades.
• Policy focus could emphasize investment in academic research and development to accumulate biopharmaceutical knowledge at the first 
stage, but also needs to transfer to firm-leading industry-academia cooperation in the following industrialization stage. 
Implications for public
Biopharmaceutical innovation requires long-term investment, which needs the strong support from the public. Considering the significant medical 
efficacy of biopharmaceutical drugs, public should provide more patience and cognitive support to develop biopharmaceutical in developing 
countries.
Key Messages 
Background
This article explores the trajectory of biopharmaceutical 
innovation in China. Biopharmaceutical whose knowledge 
base is modern biotechnology originally emerged in 
the United States in the 1970s. Modern biotechnology 
following the definition of Laage-Hellman et al1 refers to 
the biotechnology which is developed in the post-genetic 
engineering era in the 1970s. Besides, in this article we 
also define traditional biotechnology as the biotechnology 
developed before the post-genetic engineering era. Indeed 
the origin of modern biotechnology was the development 
of recombinant DNA and genetic engineering techniques in 
the early 1970s in the universities of the United States, such 
as the University of California, San Francisco, CA, USA. The 
American pharmaceutical multinational company (MNC), 
Eli Lilly, as well as the new American biopharmaceutical 
company, Genentech and the European pharmaceutical 
MNC, Kabi (Swedish), were the companies which first 
commercialized the techniques of genetic engineering and 
applied the techniques for manufacturing pharmaceuticals 
identified as the biopharmaceutical today.2 The innovation 
system of biopharmaceutical which initially emerged in the 
United States eventually spilled over to China, the second 
largest economy all over the world. However, compared with 
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the empirical analysis of biopharmaceutical innovation in the 
United States and Europe which has been well-documented by 
large quantities of the current literature,3-5 the evolution and 
transition of biopharmaceutical in China only gains limited 
notice of the existing literature.6 Even though the Chinese 
government has considered biopharmaceutical as one of the 
strategic industries which would potentially strengthen the 
leadership of the Chinese economy globally, the transition 
of government policies and its influence on the evolution 
of  biopharmaceutical innovation system presently remains 
ambiguous.
This article thus sets up the initial discussion of the evolution 
of biopharmaceutical innovation system in China through 
the perspective of sectoral innovation system (SIS). A SIS 
defines an innovation system by a set of products. The SIS 
following Malerba7 is composed of 3 elements: knowledge 
and technology, actors and networks, and institutions. In fact, 
a sector possesses a specific knowledge base and technology, 
and the actors within the network of the sectoral system are the 
individuals and organizations, including firms, universities, 
and research institutes. The actors would adopt the specific 
knowledge and technology while carry out market and non-
market interactions for the creation, production and sales of 
the set of products. The interactions of actors are recognized 
to be communication, exchange, cooperation, competition 
and command. Such interactions of actors are indeed shaped 
by institutions which refer to both the formal (such as laws and 
regulation) and informal (such as routines and culture) ones. 
Among the various institutions, government policies are the 
ones of the most essential institutions in shaping the evolution 
of the sectoral system. Since biopharmaceuticals are a set of 
products which are developed upon a particular knowledge 
and technology and innovated through the interactions 
of actors within the network, we consider SIS is the most 
suitable approach towards the analysis of biopharmaceutical 
innovation.
For the further analysis of the evolution and policy transition 
of  biopharmaceuticals in China, this article is structured as the 
following. Section Methods presents the methods developed 
for this study. Section Results describes the results, including 
ecology and efforts of firms, the exploration of universities 
and institutes, as well as the design of government policies. 
Section Discussion discusses the dynamics of sectoral 
evolution, as well as the policy transition. Finally, section 
Conclusion concludes the article.
Methods
Data Collection
We adopt 2 data sources to generate an integrated picture of 
the evolution of biopharmaceutical innovation in China. The 
2 data sources include archival documentary data and field 
interviews. Each kind of data sources is introduced below. 
Firstly, archival documentary data were collected from 
2 key documentary sources, China Food and Drug 
Administration (CFDA) and Chinese National Knowledge 
Infrastructure (CNKI). The former is the most important 
source of government documents which narrates policies 
and regulations related to biopharmaceutical in China. The 
latter is the synthetic collection of databases which include 
all the academic publications in China. Through CFDA, 
key government documents of policies and regulations 
related to biopharmaceutical were extracted. Besides, we 
used the keyword of ‘biopharmaceutical’ to search through 
CNKI and downloaded all the academic publications 
about biopharmaceutical development. The downloaded 
publications were checked manually to exclude the 
publications that were not related to biopharmaceutical in 
China, such as the review articles about biopharmaceutical 
development in the United States. 
Secondly, field interviews were also conducted. We have 
interviewed both industrial practitioners and leading 
researchers in academia. For industrial practitioners, 
Research and Development (R&D) and/or marketing 
managers from 5 Chinese biopharmaceutical companies 
which have successfully registered and produced the First-
Class New Biopharmaceutical Drugs were interviewed. 
In sum, 12 industrial practitioners were interviewed. The 
main interview questions covered company background, 
knowledge sources of their key biopharmaceutical drugs, 
internal and external R&D activities, marketing activities, 
as well as perceived industrial backgrounds and barriers. 
Every interview was approximately one to one and half 
an hour in a face-to-face way. Moreover, for leading 
researchers in academia, 2 Chinese professors majoring in 
biopharmaceutical research were interviewed to get their ideas 
about the evolution of biopharmaceutical research in Chinese 
universities and institutes, the technological cooperation 
and transfer between academia and industry, government 
support in biopharmaceutical research and industrialization, 
and their perceived barriers as well as future strategy for 
biopharmaceutical development in China.
Data Analysis
As this research was set to clarify the evolution of Chinese 
biopharmaceutical innovation system, the 2 data sources 
collected were jointly analyzed through the perspective of 
SIS. We especially paid attention to the roles of key actors, 
firms and universities, and the influence of policies. The data 
were analyzed through 5 steps. First of all, all the data were 
categorized into 3 categories: firms, universities and institutes, 
and policies. Secondly, in each category, the materials and 
data were ordered in the sequence of years. Thirdly, thematic 
analysis was carried to identify the main meanings behind 
the key events. Finally, the findings from each category 
were analyzed in a crossing way to establish the linkages 
and dynamics to illustrate the nature of biopharmaceutical 
innovation system in China.
Results
Efforts of Domestic Firms
The knowledge foundation of biopharmaceuticals was 
initially developed by China’s state-owned enterprises. In 
1949, the newly established government of the People’s 
Republic of China built up a comprehensive planned 
economy system and accelerated efforts to realise self-
sufficiency in all products, including pharmaceuticals. 
Certain state-owned enterprises were thus ordered by the 
government to produce pharmaceutical products. The 
majority of these pharmaceuticals were chemical medicines 
manufactured through chemical engineering. Only a few 
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state-owned enterprises were commanded to provide some 
primary biochemical products, such as insulin extracted 
from pig pancreases. However, most state-owned enterprises 
concentrated on the production of chemical medicines and 
regarded the manufacture of biochemical products as a minor 
task.8,9
It was not until the mid-1980s that the government ordered 
several state-owned enterprises to develop a number of 
relatively advanced biochemical products, such as vaccines 
and blood products. There were rising public concerns about 
the safety of imported blood products, such as albumin, 
immunoglobulin and blood coagulation factors. At the same 
time the demand for vaccines, especially hepatitis B vaccine, 
was also increasing due to the huge and growing population. 
Therefore, the government funded seven public research 
institutes to transfer some traditional biotechnologies such 
as fermentation methods from the United States for the 
production of blood products and vaccines. These traditional 
biotechnologies were then transferred to 30 state-owned 
enterprises that were involved in manufacture of these 
products. The state-owned enterprises eventually developed 
strong capabilities for producing these relatively advanced 
biochemical products, which they distributed all over the 
nation.10
MNCs only started to sell their biopharmaceuticals in 
China from the beginning of the 1990s. The MNCs quickly 
achieved success as dominant players in the Chinese 
market, particularly the privilege of sales in hospitals, the 
main marketing channels in China.11,[1] The domestic state-
owned pharmaceutical enterprises were thus incentivised 
to innovate their own biopharmaceuticals. The knowledge 
base of such biopharmaceuticals was modern biotechnology. 
Nevertheless, as the domestic state-owned enterprises 
had not yet accumulated sufficient knowledge of modern 
biotechnology, it proved very difficult for them to undertake 
biopharmaceutical production. On the one hand, the state-
owned enterprises could not get technology transfers from 
the MNCs, which were extremely sensitive in protecting their 
intellectual properties.12 On the other hand, these domestic 
enterprises had limited opportunities to receive practical 
knowledge of modern biotechnology from the domestic 
universities or public research institutes, as these learning 
centres focused mainly on pure academic research. As a 
result, the state-owned pharmaceutical enterprises had to 
continuously produce the relatively advanced biochemical 
products, such as the blood products and vaccines, but were 
unable to compete with MNCs in the domestic market. 
During the early 1990s, the government invested in a small 
group of new companies that gradually developed their 
capabilities for innovation in biopharmaceutical products. 
Kexing Biotech, which was set up in 1989, was the most 
successful among these new companies. Kexing was the first 
biopharmaceutical company in China, and it was jointly 
funded by four public research institutes that collaborated to 
manufacture and commercialise the result of their cooperative 
research project, namely ‘Recombinant human interferon 
α1b.’ In the mid-1990s, Kexing successfully applied genetic 
engineering for manufacturing this interferon. ‘Recombinant 
human interferon α1b’ was thus the first biopharmaceutical 
product to be developed in China.13,14 
Only in the middle 1990s did many new biopharmaceutical 
small and medium-sized enterprises (SMEs) emerged in 
China. These companies intensified the transfer of modern 
biotechnological knowledge through 3 routes. First and the 
most important route, was through Chinese scientists who 
were trained and worked in the United States and returned 
to China to set up their new businesses there.15 Many of 
these Chinese scientists had previously conducted specific 
biopharmaceutical projects, and had innovated particular 
technologies in the MNCs or at universities in the United 
States. When these Chinese scientists established their 
businesses in China, they often received venture capital from 
the government or state-owned enterprises which had a strong 
interest in biopharmaceuticals. With such fiscal support, the 
returned Chinese scientists quickly built up their capabilities 
to develop biopharmaceuticals. For example, Sunway Biotech 
was founded in 1995 by a returned Chinese scientist who had 
helped to develop one of the core genetic technologies of anti-
tumour medicine in the United States. The company received 
funding from Shanghai Industrial Investment (a state-owned 
pharmaceutical company) and Shanghai Alliance Investment 
company (a state-owned venture capital firm). Sunway also 
obtained substantial R&D funding from the government. 
With such public financial support, in 2006 the company 
successfully developed ‘recombinant human adenovirus 
type 5 injection (Oncorine),’ which was the world’s first 
oncologic medicine made from viruses. Other companies 
transferred modern biotechnology through cooperation or 
acquisition agreements between governments.16 For example, 
Biotech Pharma, which was set up in 2000, received Chinese 
government support in transferring the biotechnology for 
producing humanised monoclonal antibodies. The company 
participated in a project jointly funded by the governments 
of Cuba and China which resulted in the development of the 
anti-cancer product ‘nimotuzumab injection (taixinsheng).’17 
Moreover, some new biopharmaceutical companies benefited 
from knowledge transfers from domestic universities and 
research institutes. For instance, Chengdu Huashen Pharma, 
established in 1996, was licensed by the Fourth Military 
Medical University and developed its first product, ‘iodine 
tumour necrosis therapy injection (Licartin),’ which was the 
world’s first biopharmaceutical to target lung cancer with a 
radioimmunogenic agent.18 
In most cases, the new pharmaceutical SMEs focused on 
incremental innovations, with minor improvements to 
existing biopharmaceuticals. The firms usually did applied 
research, such as pharmacology tests, animal tests or clinical 
trials, and they were commonly involved in final marketing 
activities. These SMEs in fact relied on foreign or domestic 
academic institutions and MNCs to discover new medicines, 
and most SMEs were only involved in improving the existing 
products. Moreover, the SMEs usually delegated individuals 
or organizational agencies for marketing. Most SMEs were 
unable to insert into the main marketing channels composed 
of hospitals, and only a few of these SMEs were able to access 
to a small part of hospitals for a very short term rather 
than long term.19 With limited innovation and marketing 
capabilities, these companies were only able to struggle in the 
domestic market and were incapable to sell their products in 
foreign countries. Through targeting specific diseases, these 
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SMEs tried to avoid competition with each other and aimed 
to secure niche markets. Indeed, the diseases targeted by these 
SMEs were usually the ones which were common in China and 
fully reimbursed by the government. With a cost advantage 
and incremental development of marketing capabilities in the 
domestic market, the Chinese biopharmaceutical companies 
tended to share more and more Chinese market with the 
MNCs.20,21
Exploration of Universities and Institutes
The main role of universities until the mid-1960s was to deliver 
education in biology and pharmacy. After the establishment 
of the People’s Republic of China in 1949, only several of 
the leading universities such as Peking University, Beijing, 
China and Zhejiang University, Zhejiang, China, founded 
departments of biology and provided fundamental education 
to undergraduates. Training in pharmacy was also very 
limited, and only 11 universities had pharmacy departments. 
These schools mainly taught chemical pharmaceutical 
engineering.22 The limited efforts in biochemical research 
were centralised in several public research institutes under 
the Chinese Academy of Science. The success in creating 
‘synthetic crystalline bovine insulin’ in 1965 was then regarded 
as the greatest achievement of Chinese science.23 However, 
the Cultural Revolution suspended almost all education and 
research in universities and public research institutes from 
1966 to 1976.
Some universities began to found pharmacy departments 
near the end of the Cultural Revolution and conducted 
research into relatively advanced biochemistry. By the 
1980s there were 39 universities that provided education in 
pharmacy. Although chemical engineering was still the main 
focus of pharmacy education, more and more academics 
noticed the new developments in biochemistry.22 Also, some 
researchers in the public research institutes of the Chinese 
Academy of Science began research in biochemistry. Funded 
by the government, the universities and institutes gained 
transfers of traditional biotechnology from the United States 
in areas, such as fermentation methods to help improve the 
quality of blood products and vaccines. This accumulation 
of knowledge in the universities and institutes was later 
transferred to the state-owned enterprises for application 
in production. Then, inspired by the innovations in 
biopharmaceuticals from the United States and European 
countries during the late 1980s, Chinese scientists also began 
to practise cutting-edge research in biotechnology. In 1987, 
Chinese scientists discovered ‘recombinant human interferon 
α1b,’ which was the first Chinese biopharmaceutical developed 
through genetic engineering. This invention was transferred 
for production to Kexing Biotech in 1989).12 
Since the mid-1990s, growing numbers of pharmacy 
departments of universities and public research institutes 
conducted extensive research in biotechnology and 
biopharmaceuticals. Numerous departments and programmes 
for the study of biopharmaceuticals were founded in the 
pharmacy schools. These departments and programmes 
acquired huge amounts of R&D funding from all kinds 
of government resources, such as the Nature Science 
Foundation Committee of China, the Ministry of Science 
and Technology, the Ministry of Health (MoH), and the State 
Food and Drug Administration (SFDA). University staffs 
used such funding to do various research projects, but most 
of the money was spent on fundamental academic, including 
embryo,24 rather than applied research. The public research 
institutions were also funded by the government to conduct 
research in biotechnology. Some institutes were founded 
specifically to help China catch up with foreign achievements 
in biotechnology and to develop radical innovations in 
biopharmaceuticals. In 2005, for example, 8 ministries and 
departments jointly invested in establishing a new National 
Institute of Biological Sciences in Beijing, which aimed to 
achieve the leading academic status in the international 
arena.25
The efforts of universities and research institutes generated 
great academic achievements after the 2000s. The numbers 
of published papers and patent applications related to 
modern biotechnology and biopharmaceuticals tremendously 
increased. However, knowledge transfer from universities 
and institutes to industrial firms was limited. Indeed, the 
universities and research institutes that received significant 
government funding to conduct pure academic research 
had limited motivation to cooperate with companies. 
Furthermore, as the academic assessment and promotion 
system merely encouraged scholars to achieve academic 
publications, academics found themselves reluctant to invest 
their time to industrialise their discoveries. As a result, 
transfers of technology and spin-off companies were both 
limited. Most of the growing knowledge in biotechnology 
was still contained in the universities and research institutes, 
without being licensed for business applications.25 
Design of Government Policies
The Chinese government only noticed the development 
of biopharmaceuticals in the 1980s. While modern 
biotechnology was quickly developing in the United States 
and European countries, China’s transformation from a 
planned to a market economy in 1978 initially involved a 
policy of encouraging the development of biopharmaceuticals 
through knowledge transfers from foreign countries. 
In 1987, the Chinese government introduced its first 
policy concerning the biopharmaceutical industry, the 
‘Development Plan for Biological Products Industry.’ This 
7-year plan called for investing government funds in public 
research institutes to develop blood products and vaccines 
by using traditional biotechnology transferred from the 
United States. These traditional biotechnologies were then 
transferred to state-owned enterprises for the production 
of the biochemical products. Starting in 1989, a policy of 
‘Firm Finance Control Measures of Biological Products’ gave 
direct tax reductions to firms producing biopharmaceutical 
products, which helped them improve their financial 
performance. However, government policy mainly focused 
on supporting pure academic research. Due to the weak 
accumulation of biopharmaceutical knowledge and industrial 
infrastructure, the government did not pay much attention to 
biopharmaceutical production until the end of the 1990s.26
Since 2000, the main purpose of government policy changed. 
The new goal was for China to catch up to international 
standards and even become a world leader in biotechnology 
research. In addition to providing a faster drug registry 
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for biopharmaceutical products,26 the government’s 
policies promoted both R&D and industrial parks for 
biopharmaceutical firms. The R&D funding was directed to 
companies as well as universities and public research institutes. 
In 2002, the government founded the Key State Science and 
Technology Special Project for ‘Functional Genomics and 
Biochips.’ This initiative served to fund targeted programmes 
in universities and public research institutes.27 
However, the government gradually noticed that merely 
allocating funding to academic institutions did not speed 
up industrial development. Therefore, since 2006, the State 
Development and Reform Commission introduced ‘The 
Pharmaceutical Industry Eleventh Five Development Guidance’ 
to position the biopharmaceutical industry as one of the 
nation’s 6 key industries. This policy involved greater support 
for companies, universities, and institutes. Moreover, in 2012, 
the State Council formally identified the biomedical industry 
as one of the ‘strategic emerging industries of China.’ This 
policy shift positioned firms rather than universities as the 
key leaders in developing biopharmaceuticals in China.27 The 
evolution of policies specific to biopharmaceutical in China is 
summarized as Table 1 below.
In addition, the government adopted an industrial park 
policy to develop the biopharmaceutical industry. Indeed, 
the government hoped to rival the success of industrial parks 
for biopharmaceuticals in the United States and European 
countries. Beginning from 1991, China established numerous 
industrial parks on the national and provincial levels. Then, 
parks focusing specifically on bio-industries were widely 
founded since the beginning of 21st century. By 2006 there 
were more than 400 bio-industrial parks on the national 
and provincial levels.28 According to the Eleventh Five-Year 
Plan, the National Development and Reform Commission 
established 22 new national bio-industry bases in 4 batches, 
which gradually formed as 3 comprehensive regions for the 
biopharmaceutical industry. These regions included the 
Yangtze River Delta, Pearl River Delta, and Beijing-Tianjin-
Hebei Region. In short, before the 2000s, the main purpose 
of policy was to transfer traditional biotechnology from 
overseas, and after 2000s the aim was to catch up and even 
to lead the world in the development of biotechnology and 
innovation in biopharmaceutical products. The targets of 
policy moved from developing theoretical knowledge in 
academic institutions to enabling practical innovation in 
companies.29-31 
Discussion
Previous research has indicated that pharmaceutical 
innovation is highly related to the establishment and 
operation of innovation system.32 Especially for emerging 
pharmaceutical area like biopharmaceutical, its success 
demands more support from an innovation system.33 In fact, 
biopharmaceutical innovation system in China possessed 
modern biotechnology as its own knowledge base. The main 
actors intensively involved in the innovation were firms 
(especially SMEs), universities and institutes. While these 
actors carried out market and non-market interactions for 
the creation, production and sales of biopharmaceutical, 
the interactions of these actors were extensively shaped by 
government policies. Following the empirical analysis above, 
we generates 4 findings that are worth of further discussion.
First, biopharmaceutical in China was established through 
international knowledge transfer. Modern biotechnology such 
as genetic and monoclonal antibody was only introduced to 
China in the mid-1990s from overseas, and the introduction 
of modern biotechnology was through entrepreneurship. 
The new biopharmaceutical companies which were mainly 
set up by the Chinese scientists trained in the United States 
became the main actors to innovate biopharmaceuticals 
since the mid-1990s. In particular, the establishment of 
science park in major cities like Shanghai City attracted 
many returnees who transferred mature biopharmaceutical 
science and technologies to China.29 At the same time, local 
pharmaceutical firms experimented to get biopharmaceutical 
technology sources from overseas through diverse forms like 
patent acquisition or technology cooperation.28 With these 
direct knowledge transfer, China could rapidly catch-up with 
the frontiers of global biopharmaceutical development, which 
significantly mitigate its lag behind the global pharmas and 
established its industrial infrastructure rapidly.
Second, local government and the state-own enterprises 
which were dominant in manufacturing relatively 
advanced biochemical products such as blood products 
and vaccines became the most important investors of these 
new biopharmaceutical companies. Biopharmaceutical 
development always faces great financial risks and often 
requires the support of venture capital.34 However, in China 
the role of venture capital is replaced by local government 
and pharmaceutical state-own enterprises. Local government 
seeks to stimulate the foundation of biopharmaceutical 
industry locally; local pharmaceutical state-own enterprises 
that are mostly controlled by local governments also want to 
invest in biopharmaceutical to increase their profitability in 
the future. While for new biopharmaceutical companies such 
kind of financial support is less flexible than venture capital, 
local government and state-own enterprises in fact provided 
more stable and additional benefits like policy support to the 
new biopharmaceutical companies.
Third, universities have extensively accumulated knowledge 
of biopharmaceuticals from the 1980s until the 2010s. 
Nevertheless, with the institutions which tended to 
encourage pure academic research, universities had limited 
incentives to transfer biotechnologies to the industry. But it 
is observed that the universities and institutes in China are 
more and more involved in technology commercialization of 
biopharmaceuticals.35 Through indirect technology consulting 
and direct technology cooperation, Chinese universities and 
institutes are accelerating their integration with industry. 
Table 1. Biopharmaceutical policy evolution in China
Year Policy
1987 ‘Development Plan for Biological Products Industry’
1989 ‘Firm Finance Control Measures of Biological Products’
2002 Key State Science and Technology Special Project for ‘Functional Genomics and Biochips’
2006
‘The Pharmaceutical Industry Eleventh Five Development 
Guidance’ to position the biopharmaceutical industry as one of 
the nation’s 6 key industries
2012 Biomedical industry as one of the ‘strategic emerging industries of China’
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While the direct transfer of innovative biopharmaceuticals is 
not expected in the short term, the knowledge accumulation 
in the last three decades is expected to contribute to the 
industrial development.
Forth, the transition of the Chinese government’s policies 
continuously shapes the evolution of biopharmaceutical 
sector. In the 1980s, the main focus of national policies 
was to manufacture primary biochemical products such as 
blood products and vaccines to supply national demands. 
Afterwards, the Chinese government began to encourage 
industrial development of biopharmaceutical products in the 
1990s. Entering into the 21st century the government even 
recognized biopharmaceuticals as the key strategic industry 
of the nation and the emphasis of policies was to catch-up 
even to lead the innovation of biopharmaceuticals in the 
international arena. Besides, the types of policies also change. 
Before the mid-2000s, the government mainly provided R&D 
funding to universities and research institutes. However, after 
the 2000s the government also considered the importance of 
the involvement of firms and provided not only R&D funding, 
but bio-industrial parks to develop biopharmaceuticals. 
Indeed the existing literature has noticed the significant role 
of Chinese government in directing biotechnology R&D.36 
The government’s policies have transited in an evolutionary 
way to establish a competitive biopharmaceutical sector.
While China has made its first step in promoting 
biopharmaceutical sector through founding an innovation 
system, it faces a lot of challenges ahead, particularly compared 
with the advanced biopharmaceutical economies.20,21 Currently 
biopharmaceutical is still a small sector in China, and for the 
further growth of the industry more synthetic policies should 
be implemented. The Chinese biopharmaceutical sector now 
highly relies on the new domestic enterprises to develop 
new products,37 and the efforts for the commercialization 
of biopharmaceutical products totally rely on the marketing 
capabilities of the new SMEs. Nevertheless, these SMEs 
with relatively limited resources to invest in the sales of 
biopharmaceuticals are difficult to compete with MNCs 
even in the domestic market. In practice, the Chinese 
government extensively supports the research and innovation 
of biopharmaceuticals in the early stage of development. Yet, 
while commercialization was totally burdened by domestic 
SMEs, once the biopharmaceutical SMEs lacks financial 
resources for further sales in China, they will lack resources 
for the further innovation of the biopharmaceutical products. 
The further development of biopharmaceutical products by 
firms would thus suspended, but presently there is no policy 
supports towards the successful sales of biopharmaceutical 
products. Therefore, the future implementation of 
biopharmaceutical policies must also consider the aspects of 
sales, including the public purchase of hospitals. In addition, 
global pharmas are trying to integrate the rising Chinese 
biopharmaceutical R&D into their own global R&D chain and 
thus compete with domestic SMEs for the resources of early 
stage results of R&D.38-40 The impact of MNCs on the Chinese 
biopharmaceutical innovation system needs longitudinal 
observation.
Conclusion 
In sum, the biopharmaceutical in China was developed 
through the establishment of an innovation system in an 
evolutionary way. The dynamics of biopharmaceutical 
innovation system in China has emerged since the late 1980s 
and keep evolving up to date. In fact, the original knowledge 
base of the Chinese biopharmaceutical sector was traditional 
biotechnology, and modern biotechnology was introduced 
into the sector only in the late 1980s mainly through a 
group of Chinese scientists trained in the United States. 
In practice, the main actors of biopharmaceuticals were 
initially the state-own enterprises and then a group of new 
biopharmaceutical SMEs which were set-up in the 2000s and 
invested by public funds or state-own enterprises. Targeting 
the specific segment of diseases, these new companies 
dominated the sales of particular biopharmaceuticals in the 
domestic market but lacked the capability to compete with 
their international counterparts in the foreign markets. The 
Chinese government considered biopharmaceutical as the 
strategic industry and provided strong guidance to support 
the development of biopharmaceuticals. It is the dynamics 
among these components of innovation system that promoted 
the development of biopharmaceutical in China.
Based on the findings from this study, there are several 
implications that could be referred. First, international 
knowledge transfer is necessary to set up the knowledge 
base and shorten the technological catch-up period of 
biopharmaceutical. Second, international returnees could 
play rising roles in realizing biopharmaceutical transfer 
and innovation rather than formal international agreement. 
However, cooperation among organizations, particularly, 
between firms and academia will contribute in a relatively 
long term. Third, specific policy design for R&D and 
industrial development are crucial for innovation and 
commercialization of biopharmaceutical technology.
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Endnotes 
[1] There is no formal statistical data officially published by the Bureau of 
Statistics in China. However, according to the survey done by Chinese 
Pharmaceutical Enterprises Association in 2009, hospitals played the role as 
the main channels of pharmaceutical sales. MNCs with mature marketing skills 
towards hospitals had the prior competitive advantage in marketing than the 
domestic firms. In fact, while the management of the hospitals used to charged 
higher prices in pharmaceuticals to supplement the deficits of clinical services, 
the prices of pharmaceuticals in China were usually much higher than costs. 
The dominance of MNCs was even more obvious since 2000 when the hospitals 
were commanded by the government to purchase the pharmaceuticals through 
legal and transparent processes and to reveal the quality of pharmaceuticals. 
MNCs which were able to produce high quality pharmaceuticals controlled 
Hu and Chung
International Journal of Health Policy and Management, 2015, 4(12), 823–829 829
50% of the pharmaceutical market, and the rest of the 50% market was 
shared by large numbers of domestic firms. The main products of MNCs were 
biopharmaceuticals, while the products of domestic firms were chemical generic 
medicines.11 According to the survey, MNCs were indeed dominant in the sales 
of biopharmaceuticals.
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